Jeffrey Miller, MD

The deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.

The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.

The professor of medicine and University of Minnesota Medical School discussed the advantages and unmet needs of natural killer cells in oncology.